Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up

NCT07678268 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

78

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infection
Antiretroviral Therapy
Lentivirus Infections

Interventions

DRUG: Dual therapy: darunavir/cobicistat + lamivudine
DRUG: Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine

Sponsor

Instituto Mexicano del Seguro Social